French DRG (diagnosis-related group) ratings threaten innovative/orthopaedic products
This article was originally published in Clinica
The French medical device industry is lobbying the government to ensure that the new diagnosis-related group (DRG) scheme, known locally at the T2A system, does not drive payments for devices so low that there is no possibility of using innovative products. Medical professionals will need to retain the option of having access to such products, or those that offer additional benefits, for example in terms of patient recovery time or comfort.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.